Global Ulcerative Colitis Market is expected to rise gradually to an estimated value of USD 10.51 billion by 2026, registering a CAGR of 5.4% in the forecast period of 2019-2026. This rise in market value can be attributed to the increasing awareness and concerns regarding the health of patients, large number of pipeline molecule and government investments.
Ulcerative colitis is a chronic disease that affects the colon of large intestine. It is characterized by inflammation in the large intestine, and the symptoms include blood in the stool, diarrhea and abdominal pain. According to CDC, in 2015, there were approximately 3.0 million people having IBD (either Crohn’s Disease or ulcerative colitis), other report from NCBI says that the highest reported prevalence values were in Europe (ulcerative colitis 505 per 100 000 in Norway) and North America (ulcerative colitis 286 per 100 000 in the USA), almost more than half of these cases could have been avoided with the availability of proper medical treatment. This significant number is expected to act as a driver to the market growth.
Get Free Sample Copy of Report Here: @ https://databridgemarketresearch.com/request-a-sample/?dbmr=global-ulcerative-colitis-market
Key Market Competitors: Global Ulcerative Colitis Market
Few of the major competitors currently working in the ulcerative colitis market are Allergan, Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Bayer AG, UCB S.A., Perrigo Company plc, Pfizer Inc., Johnson & Johnson Services, Inc., GlaxoSmithKline plc, Eli Lilly and Co., Sanofi Aventis A/S, AstraZeneca, Merck & Co., Inc., InDex Pharmaceuticals Holding AB, AJINOMOTO CO.,INC., Abbott, Circle33, LLC, BioLineRx, CELGENE CORPORATION, Mitsubishi Tanabe Pharma Corporation, Salix Pharmaceuticals, Inc. and few among others.
Market Drivers
• Rise in the incidence and prevalence rate of the disease will drive the growth of the market
• Large number of pipeline molecule will help the market to grow
• Rise in the government and non-government investment in the R&D
Market Restraints
• Strict government regulations Is restraining the market growth
• Patent expiry of blockbuster drugs will result in generic and biosimilar competition
• Lower incidence rate in Asia- pacific regions restricts the growth of market in that particular area
Table of Content:

Part 01: Executive Summary
Part 02: Scope of The Report
Part 03: Global Ulcerative Colitis Market Landscape
Part 04: Global Ulcerative Colitis Market Sizing
Part 05: Global Ulcerative Colitis Market Segmentation by Product
Part 06: Five Forces Analysis
Part 07: Customer Landscape
Part 08: Geographic Landscape
Part 09: Decision Framework
Part 10: Drivers and Challenges
Part 11: Market Trends
Part 12: Vendor Landscape
Part 13: Vendor Analysis
Get Detailed TOC: @https://databridgemarketresearch.com/toc/?dbmr=global-ulcerative-colitis-market
Segmentation: Global Ulcerative Colitis Market
• By Type
o Ulcerative Proctitis
o Proctosigmoiditis
o Left-Sided Colitis
o Pancolitis or Universal Colitis
o Fulminant Colitis
• By Drug Type
o Anti-Inflammatory Drugs
o Aminosalicylates
o Corticosteroids
o Anti-TNF biologics
o Immunosuppressant
o Calcineurin Inhibitors
o Other Drug Types
• By Molecule Type
o Small Molecules
o Biologics
• By End- User
o Hospital Pharmacies
o Retail Pharmacies
o Drug Store
o E-commerce
• By Route of Administration
o Parentral
o Oral
By Geography
• Asia Pacific
o China
o South Korea
o Japan
o India
o Australia
o Singapore
• North America
o US
o Canada
o Mexico
• Europe
o Russia
o Turkey
o Switzerland
o Spain
o France
o Germany
o Italy
o UK
• South America
o Brazil
o Argentina
o Rest of South America
• Middle East & Africa
o South Africa
o Egypt
o United Arab Emirates
Key Developments in the Market:
• In December 2017, Boehringer Ingelheim International GmbHannounced a collaborative agreement on the discovery and development of orally available novel Locked Nucleic Acid (LNA) oligonucleotides for the treatment of inflammatory bowel diseases (IBDs) with Roche. Together, Boehringer Ingelheim and Roche will leverage complementary expertise and innovative LNA technology to bring novel treatment approaches to IBD patients.
• In February 2018, Regentys, a regenerative medicine company, announced its partnership with Cook Biotech Inc., to develop a novel treatment for ulcerative colitis. Under the terms, Cook Biotech will develop and manufacture Regentys’ licensed clinical product, ECMH Rectal Solution (Extracellular Matrix Hydrogel), which will be used in first-in-man clinical studies conducted by Regentys in 2018.
Inquiry Before Buying @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-ulcerative-colitis-market
Competitive Analysis: Global Ulcerative Colitis Market
Global ulcerative colitis market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of ulcerative colitis market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing [email protected] . We are content with our glorious 99.9 % client satisfying rate.

Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]